The data come from a commercial insurance claims database that requires a data sharing agreement and data license for access. To apply for access to the data please visit <https://www.optum.com/content/dam/optum/resources/productSheets/Clinformatics_for_Data_Mart.pdf> (Email: <connected@optum.com>)

Introduction {#sec007}
============

Desmopressin acetate is a synthetic analog of vasopressin that acts within the collecting ducts to increase water reabsorption in the kidneys and reduce urine production \[[@pmed.1002930.ref001],[@pmed.1002930.ref002]\]. It was initially approved by the Food and Drug Administration (FDA) in 1978 for the treatment of diabetes insipidus and certain rare bleeding disorders \[[@pmed.1002930.ref003]\]. Its approved uses were subsequently extended to include primary nocturnal enuresis in children \[[@pmed.1002930.ref004]\], but this indication was removed from the drug label in 2007 after 61 cases of hyponatremia-related seizures were reported to the FDA \[[@pmed.1002930.ref001]\]. The drug label carried a warning for the risk of hyponatremia \[[@pmed.1002930.ref005]\], but a boxed warning was not mandated.

Desmopressin is still prescribed by some physicians for adults with nocturia \[[@pmed.1002930.ref006]--[@pmed.1002930.ref008]\]. Nocturia is defined by the International Continence Society as waking from sleep to void one or more times \[[@pmed.1002930.ref009]\]. Nocturia is often multifactorial in etiology and may be due to an underlying sleep disorder, impaired bladder storage (including reduced bladder capacity or bladder overactivity), urinary factors (including global or nocturnal polyuria), or other factors, including medication or alcohol use \[[@pmed.1002930.ref010]\]. Meta-analyses have identified that desmopressin slightly reduces the absolute number of nocturnal voids per night (i.e., about 0.5 fewer nocturnal voids) compared to placebo but not compared to alpha-blockers (for example, tamsulosin) \[[@pmed.1002930.ref002],[@pmed.1002930.ref011]\].

Despite adult nocturia being an off-label indication, this use of desmopressin has been supported by a number of professional associations, including the American Academy of Family Physicians \[[@pmed.1002930.ref008],[@pmed.1002930.ref012]\]. For this indication, a meta-analysis identified that desmopressin use was associated with a 5.1-fold (95% confidence interval \[CI\] 3.0, 8.8) higher odds of hyponatremia compared to placebo, with approximately 5% of patients prescribed desmopressin experiencing hyponatremia \[[@pmed.1002930.ref002]\]. Since the clinical trials defined hyponatremia as a decrease in serum sodium level identified through laboratory monitoring, this risk may not be clinically relevant. As a result, the severity of hyponatremia reported in clinical trials may be underestimated because the medication can be stopped before the sodium level decreases and patients become symptomatic and seek medical attention.

Quantifying the potential risks facing adult patients taking desmopressin has taken on added importance because in 2017, a new intranasal formulation of desmopressin was approved by the FDA \[[@pmed.1002930.ref001]\]. Like the old formulation, the main active ingredient is desmopressin acetate, but the new formulation also contains an excipient designed to enhance absorption. The primary objective of this study was to assess the rate of hyponatremia in routine clinical care for patients prescribed this older formulation of desmopressin and determine how it compared to the results derived from the clinical trials.

Methods {#sec008}
=======

Study population and design {#sec009}
---------------------------

We conducted a population-based, new-user cohort study using the nationwide US commercial insurance claims database Optum© Clinformatics® Data Mart \[[@pmed.1002930.ref013]\]. This database provides deidentified longitudinal, individual-level data on patient demographics, healthcare utilization, medical diagnoses, diagnostic tests, clinical procedures, outpatient laboratory results, and pharmacy dispensing of drugs to over 20 million people in the US.

We compared patients over the age of 50 years who were newly prescribed desmopressin or oxybutynin between February 1, 2006 (the start of available data) and February 1, 2017 (last available data). We only included patients over the age of 50 because younger patients are more likely to receive desmopressin for another indication (for example, diabetes insipidus or bleeding disorders). Oxybutynin was chosen as the comparator because it too is sometimes prescribed to patients with nocturia but is not associated with hyponatremia. Using an active comparator, rather than a nonuser comparator, improves confounding control and study validity \[[@pmed.1002930.ref014],[@pmed.1002930.ref015]\]. The date of the first prescription for desmopressin or oxybutynin was used as the cohort entry date. "New users" of desmopressin or oxybutynin were defined as patients without a prior prescription for either medication in the 180 days prior to the index date. The 180-day time period is the most commonly used for pharmacoepidemiologic studies using US insurance claims databases, and prior studies have demonstrated similar results when a longer time period is used \[[@pmed.1002930.ref016],[@pmed.1002930.ref017]\].

As a sensitivity analysis, we used an alternate comparator to oxybutynin because the clinical indications for oxybutynin and desmopressin only partially overlap. Tamsulosin was selected as the alternate comparator because it is prescribed for benign prostatic hypertrophy, which is a common cause of nocturia, and it is not known to cause hyponatremia \[[@pmed.1002930.ref011]\],

Patients receiving both desmopressin and oxybutynin on the cohort entry date were excluded. To ensure all patients had at least 180 days of baseline data (i.e., data prior to the index date), we excluded those with less than 180 days of baseline data. For example, if a patient's insurance coverage started September 1 2017, and they received desmopressin on September 2 2017, then they would not be included because we would only have 1 day of available baseline data for this patient. Patients with any of the following characteristics in the 180 days prior to cohort entry were also excluded: recent hospitalization or a diagnosis of malignancy, hyponatremia, diabetes insipidus, hemophilia A, Von Willebrand disease, or end-stage renal disease requiring dialysis. Our study focused on outpatient prescriptions for desmopressin or its comparator rather than inpatient prescribing.

The study was approved by the institutional review board at Brigham and Women's Hospital, and a valid data licensing agreement to use Optum Clinformatics was in place.

Cohort follow-up {#sec010}
----------------

Follow-up began the day after cohort entry and continued until the end of the study period, end of continuous health coverage enrollment, occurrence of a study outcome, discontinuation of the initial medication or switching to or adding the comparator medication, end of available patient data, 365 days, or death. A medication was considered discontinued if 14 days elapsed after the expiration of the last prescription's supply without the prescription being refilled.

Study outcomes {#sec011}
--------------

The primary outcome was the rate of hyponatremia (per 1,000 person-years) after being prescribed desmopressin or oxybutynin. While outpatient interactions are typically limited to a single diagnostic code, hospitalizations are associated with a single primary position diagnosis code and multiple secondary position diagnosis codes. For our primary analysis, we assessed hyponatremia as the primary position diagnosis ICD9 or ICD10 code (inpatient or outpatient) following prescription of desmopressin or oxybutynin. As a sensitivity analysis, we restricted the outcome to primary position inpatient codes. Inpatient codes for hyponatremia have been validated previously and have adequate specificity (\>99%) and positive predictive value (\>90%) but limited sensitivity (\<30%) \[[@pmed.1002930.ref018]\]. As a secondary outcome, we assessed the rate of hyponatremia within the 30 days after being prescribed desmopressin or oxybutynin. This analysis was performed because hyponatremia generally occurs soon after starting desmopressin.

Baseline covariates {#sec012}
-------------------

During the 180 days preceding cohort entry (i.e., the date desmopressin or oxybutynin was prescribed), we collected data on chronic medical conditions (for example, hypertension, coronary artery disease, stroke), risk factors for hyponatremia (for example, baseline serum sodium, diuretic use, antidepressant use), healthcare utilization (for example, recent hospitalization, emergency room visit), and concomitant medications (for example, antihypertensives, antipsychotics) for each patient.

Statistical analysis {#sec013}
--------------------

Propensity-score (PS) matching was used to adjust for baseline characteristics. The probability of being prescribed desmopressin versus oxybutynin or tamsulosin was calculated through a multivariable logistic regression model that contained all baseline covariates with the exception of laboratory values. Laboratory values were not included because these data were only available for about 20% of patients, and a PS cannot be calculated when there are missing covariate data. There were no other missing data. Covariate balance before and after PS matching was assessed using standardized differences. A standardized difference less than of 0.1 indicates adequate balance between groups \[[@pmed.1002930.ref019]\].

The estimated PS was used to match 1:1 new users of desmopressin with new users of oxybutynin or tamsulosin with a caliper size of 0.05 on the propensity scale. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% CIs of the primary outcome. In a sensitivity analysis, we performed a stratified analysis using deciles of the PS. All analyses were performed using Aetion platform version 3.11 and R version 3.5.0. Aetion has previously been validated by accurately repeating a range of previously published studies and by replicating or predicting clinical trial findings \[[@pmed.1002930.ref020]--[@pmed.1002930.ref022]\].

Results {#sec014}
=======

We identified 232,749 adults who satisfied study inclusion and exclusion criteria ([S1A Appendix](#pmed.1002930.s001){ref-type="supplementary-material"}). Of those, 229,612 were newly prescribed oxybutynin and 3,137 were newly prescribed desmopressin. Adults prescribed desmopressin were more likely to be men, to be younger, to have a slightly higher creatinine, to have benign prostatic hyperplasia, and to have filled a prescription for steroids in the preceding 180 days. Adults prescribed oxybutynin were more likely to have a diagnosis of hypertension or obesity and to have filled a prescription for a diuretic, angiotensin-converting enzyme (ACE) inhibitor, or an older generation antihypertensive in the preceding 180 days ([S1B Appendix](#pmed.1002930.s001){ref-type="supplementary-material"}). The majority of the remaining baseline characteristics (including baseline serum sodium) were balanced before PS matching. The median duration of follow-up was 51 days (interquartile range: 42,121) ([S1C Appendix](#pmed.1002930.s001){ref-type="supplementary-material"}).

After 1:1 PS matching, we were able to match 100% of adults prescribed desmopressin. Overall, the mean age was approximately 70 years, 45% were female, and the baseline sodium was identical for the two groups at 140 mmol/L (normal 135--145). The major risk factors for hyponatremia were relatively rare in both groups (for example, diuretic use) ([Table 1](#pmed.1002930.t001){ref-type="table"}) and were well-balanced.

10.1371/journal.pmed.1002930.t001

###### Baseline patient characteristics.

![](pmed.1002930.t001){#pmed.1002930.t001g}

                                                                       Unmatched         Propensity score matched                                           
  -------------------------------------------------------------------- ----------------- -------------------------- ------- --------------- --------------- -------
  Cohort entry date:                                                                                                0.045                                   0.056
  ---first quarter                                                     60,369 (26.3%)    771 (24.6%)                        843 (26.9%)     771 (24.6%)     
  ---second quarter                                                    51,434 (22.4%)    715 (22.8%)                        716 (22.8%)     715 (22.8%)     
  ---third quarter                                                     57,880 (25.2%)    835 (26.6%)                        807 (25.7%)     835 (26.6%)     
  ---fourth quarter                                                    59,929 (26.1%)    816 (26.0%)                        771 (24.6%)     816 (26.0%)     
  Sex, female                                                          172,395 (75.1%)   1,415 (45.1%)              0.643   1,409 (44.9%)   1,415 (45.1%)   0.004
  Age, mean (SD)                                                       71.79 (13.83)     69.84 (14.28)              0.139   70.03 (13.07)   69.84 (14.28)   0.014
  Serum sodium, mean, mmol/L[\*](#t001fn002){ref-type="table-fn"}      140 (2.78)        140 (2.96)                 0.012   140 (3.10)      140 (2.96)      0.007
  Serum creatinine, mean, mg/dL[\*](#t001fn002){ref-type="table-fn"}   0.95 (0.35)       1.01 (0.34)                0.162   0.97 (0.29)     1.01 (0.34)     0.127
  **Comorbidities**                                                                                                                                         
  Chronic kidney disease                                               12,521 (5.5%)     134 (4.3%)                 0.055   134 (4.3%)      134 (4.3%)      0
  Hypertension                                                         125,524 (54.7%)   1,518 (48.4%)              0.126   1,491 (47.5%)   1,518 (48.4%)   0.017
  Coronary artery disease                                              31,107 (13.5%)    427 (13.6%)                0.002   442 (14.1%)     427 (13.6%)     0.014
  Heart failure                                                        14,492 (6.3%)     143 (4.6%)                 0.077   146 (4.7%)      143 (4.6%)      0.005
  Ischemic stroke or TIA                                               9,865 (4.3%)      101 (3.2%)                 0.057   106 (3.4%)      101 (3.2%)      0.009
  BPH                                                                  22,495 (9.8%)     735 (23.4%)                0.373   742 (23.7%)     735 (23.4%)     0.005
  **Medications**                                                                                                                                           
  Beta blocker                                                         58,518 (25.5%)    662 (21.1%)                0.104   688 (21.9%)     662 (21.1%)     0.02
  Diuretic                                                             45,715 (19.9%)    417 (13.3%)                0.179   412 (13.1%)     417 (13.3%)     0.005
  ACEi                                                                 61,553 (26.8%)    657 (20.9%)                0.138   694 (22.1%)     657 (20.9%)     0.029
  NSAIDS                                                               39,904 (17.4%)    488 (15.6%)                0.049   468 (14.9%)     488 (15.6%)     0.018
  Oral steroids                                                        27,085 (11.8%)    563 (17.9%)                0.174   551 (17.6%)     563 (17.9%)     0.01
  Antidepressants                                                      76,017 (33.1%)    942 (30.0%)                0.066   946 (30.2%)     942 (30.0%)     0.003
  Antibiotics                                                          82,496 (35.9%)    1,194 (38.1%)              0.044   1,191 (38.0%)   1,194 (38.1%)   0.002
  **Healthcare Utilization**                                                                                                                                
  Colonoscopy                                                          9,950 (4.3%)      160 (5.1%)                 0.036   166 (5.3%)      160 (5.1%)      0.009
  Flu shot                                                             34,317 (14.9%)    450 (14.3%)                0.017   464 (14.8%)     450 (14.3%)     0.013
  Family doctor visit                                                  152,959 (66.6%)   2,043 (65.1%)              0.031   2,063 (65.8%)   2,043 (65.1%)   0.013
  ER visit                                                             38,729 (16.9%)    462 (14.7%)                0.059   454 (14.5%)     462 (14.7%)     0.007

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitor; BPH, benign prostatic hypertrophy; ER, emergency room; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation; SDiff, standardized difference; TIA, transient ischemic attack.

\*Available for approximately 20% of patients.

Rate of hyponatremia (oxybutynin comparator) {#sec015}
--------------------------------------------

In the unmatched population, there were 114 patients diagnosed with hyponatremia after being prescribed desmopressin (146 events per 1,000 person-years) compared to 836 patients who were prescribed oxybutynin (13 events per 1,000 person-years). This corresponded to an 11-fold higher rate of hyponatremia with desmopressin compared to oxybutynin (HR = 11.42; 95% CI: 9.39, 13.88; *p* \< 0.01; [Table 2](#pmed.1002930.t002){ref-type="table"}). In the PS-matched population, there were 114 patients who were diagnosed with hyponatremia after being prescribed desmopressin (146 events per 1,000 person-years) compared to nine patients who were prescribed oxybutynin (11 events per 1,000 person-years). This corresponded to a 13-fold increased rate of hyponatremia with desmopressin compared to oxybutynin (HR = 13.19; 95% CI: 6.69, 26.01; *p* \< 0.01; [Fig 1](#pmed.1002930.g001){ref-type="fig"}). Stratifying the PS into deciles provided nearly identical results (HR = 13.06; 95% CI: 10.45,16.32; *p* \< 0.01).

![Kaplan--Meier curve for PS-matched rate of hyponatremia.\
PS, propensity score.](pmed.1002930.g001){#pmed.1002930.g001}

10.1371/journal.pmed.1002930.t002

###### Rate of hyponatremia.

![](pmed.1002930.t002){#pmed.1002930.t002g}

                                Unmatched   PS-Matched                                 
  ----------------------------- ----------- ---------------------------------- ------- ----------------------------------
  Number of patients            229,612     3,137                              3,137   3,137
  Number of person-years        66,438      782                                850     782
  Number of events              836         114                                9       114
  Rate per 1,000 person-years   12.58       145.78                             10.59   145.78
  HR (95% CI)                   Ref         11.42 (9.39, 13.88), *p* \< 0.01   Ref     13.19 (6.69, 26.01), *p* \< 0.01

**Abbreviations:** CI, confidence interval; HR, hazard ratio; PS, propensity score; Ref, reference.

Similar results were observed when the rate of hyponatremia within 30 days of receiving either medication was assessed ([Table 3](#pmed.1002930.t003){ref-type="table"}). Specifically, 77 patients prescribed desmopressin experienced the outcome (314 per 1,000 person-years) compared to 278 patients prescribed with oxybutynin (15 per 1,000 person-years). After PS matching, this corresponded to a 19-fold increased rate of hyponatremia with desmopressin compared to oxybutynin (HR = 19.41; 95% CI 7.11, 52.99; *p* \< 0.01).

10.1371/journal.pmed.1002930.t003

###### Rate of hyponatremia within 30 days.

![](pmed.1002930.t003){#pmed.1002930.t003g}

                                Unmatched   PS-Matched                                  
  ----------------------------- ----------- ----------------------------------- ------- ----------------------------------
  Number of patients            229,612     3,137                               3,136   3,136
  Number of person-years        18,314      245                                 247     245
  Number of events              278         77                                  4       77
  Rate per 1,000 person-years   15.18       313.99                              16.21   314.1
  30-day risk of hyponatremia   0.12%       2.50%                               0.13%   2.50%
  HR                            Ref         20.71 (16.09, 26.65), *p* \< 0.01   Ref     19.41 (7.11, 52.99), *p* \< 0.01

**Abbreviations:** HR, hazard ratio; PS, propensity score; Ref, reference.

In our sensitivity analysis that defined hyponatremia using the primary position inpatient diagnosis code alone, 30 patients prescribed desmopressin were hospitalized with hyponatremia (38 per 1,000 person-years) compared to 136 patients prescribed oxybutynin (2 events per 1,000 person-years). After PS matching, this corresponded to a nearly 30-fold higher rate of hyponatremia hospitalization (HR = 29.83; 95% CI 4.11, 216.45; *p* \< 0.01).

Rate of hyponatremia (tamsulosin comparator) {#sec016}
--------------------------------------------

We identified 532,433 adults who were newly prescribed tamsulosin and 3,031 who were newly prescribed desmopressin. Adults prescribed desmopressin were less likely to be male and to have benign prostatic hyperplasia or cardiovascular disease. Adults prescribed tamsulosin were less likely to be prescribed steroids, anxiolytics/antidepressants, or medications for dementia. After PS matching, these characteristics and all other measured characteristics were well balanced.

In the unmatched population, there were 134 patients who were diagnosed with hyponatremia after being prescribed desmopressin (177 events per 1,000 person-years) compared to 1,466 patients after being prescribed tamsulosin (8.3 events per 1,000 person-years). This corresponded to a 20-fold higher rate of hyponatremia with desmopressin compared to tamsulosin (HR = 20.00; 95% CI: 16.74, 23.86; *p* \< 0.01). In the PS-matched population, there were 134 patients who were diagnosed with hyponatremia after being prescribed desmopressin (177 events per 1,000 person-years) compared to 11 patients who were prescribed tamsulosin (14.5 events per 1,000 person-years). This corresponded to a 12-fold higher rate of hyponatremia with desmopressin compared to tamsulosin (HR = 12.10; 95% CI: 6.54, 22.37; *p* \< 0.01). In our PS-matched sensitivity analysis restricted to 30 days of follow-up, an increased rate of hyponatremia with desmopressin compared to tamsulosin was also apparent (HR = 29.23; 95% CI: 9.31, 91.84; *p* \< 0.01).

Discussion {#sec017}
==========

In this large cohort study of older adults who were newly prescribed desmopressin, we identified an increased rate of hyponatremia diagnosis soon after the medication was prescribed. The findings were robust regardless of the comparator medication used and were also observed using a shorter follow-up period of 30 days. These findings raise concerns about the safety of this formulation of desmopressin, particularly if the medication is being used off-label for the treatment of nocturia.

The increased risk of hyponatremia associated with desmopressin is consistent with published meta-analyses of clinical trials \[[@pmed.1002930.ref002]\]. However, we found that the absolute rate of hyponatremia was approximately 146 per 1,000 person-years, which is many-fold higher than rates reported in the clinical trial literature. One reason for the lower rate observed in clinical trials may be that trial participants have closely monitored serum sodium levels. Frequent laboratory monitoring allows for treatment discontinuation if the sodium level begins to drop and approaches, but does not yet reach, the cutoff for hyponatremia. In addition, the patients included in our real-world cohort were at higher risk for hyponatremia because they were older and had more comorbid conditions than those in the trials included in the meta-analysis \[[@pmed.1002930.ref002],[@pmed.1002930.ref011]\].

An alternate explanation for the higher rate of hyponatremia we observed might be reverse causation because some patients with severe hyponatremia are treated with desmopressin. We think this is unlikely because we excluded patients with a recent diagnosis of hyponatremia and because the baseline serum sodium values for the patients who had laboratory measures were normal. It is possible we may have missed some patients who were hospitalized for another diagnosis but also had hyponatremia during the hospitalization. However, we think this is also unlikely because we excluded all patients with a recent hospitalization within the preceding 180 days.

Another potential limitation of our study is unmeasured confounding. For example, we did not have access to some over-the-counter medications that are associated with hyponatremia (for example, nonsteroidal anti-inflammatory drugs) or other risk factors for hyponatremia (for example, low-solute diet coupled with high water intake, alcohol use). Furthermore, we identified hyponatremia using insurance claims diagnoses, which have acceptable specificity but poor sensitivity. Another limitation is that we assumed censoring was noninformative. While we included a grace period of up to 14 days after treatment discontinuation to identify potential study outcomes during this time period, we may have missed outcomes if, for example, the patient was censored because they died. Finally, an important limitation is that we lacked the sample size to calculate the rate of hyponatremia with various doses of desmopressin.

Quantifying the potential risks facing adult patients taking desmopressin has taken on added importance because, in 2017, a new intranasal formulation of desmopressin was approved by the FDA for the treatment of nocturia due to nocturnal polyuria \[[@pmed.1002930.ref001]\]. The new formulation contains an excipient designed to enhance absorption across the nasal mucosa. In clinical trials of the intranasal formulation of desmopressin, approximately 5% of patients developed mild hyponatremia, and 1% developed severe hyponatremia \[[@pmed.1002930.ref001]\]. Since the new formulation of intranasal desmopressin was only marketed in 2018, data for its use in routine care are not yet available. However, it will be important to investigate outcomes from its clinical use using similar methods described in this study to monitor how the risk of hyponatremia observed in the pivotal clinical trials will compare to the risk in routine practice.

Conclusions {#sec018}
===========

The observed rate of hyponatremia in the 30 days after initiation of an older formulation of desmopressin of 314 per 1,000 person-years was higher than the reported rate in prior clinical trials. This increased rate of subsequent hyponatremia was observed in comparison to use of other medications indicated for lower urinary tract symptoms. These risks should be clearly communicated to patients prescribed this formulation of desmopressin. This increased rate of hyponatremia may also be relevant to patients considering use of a newer formulation of desmopressin that was recently approved by the FDA for the treatment of nocturnal polyuria. Real-world studies to quantify the risk of hyponatremia with this newer formulation will be necessary to ensure the risks do not outweigh the benefits.
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